Indeed, Mellado and colleagues demonstrate that blocking the recruitment of inflammatory monocytes by the systemic administration of an anti-CCR2 antagonist (CCR2-05) monoclonal antibody in a cynomolgus monkey model delayed allergic reactions and reduced the number of inflammatory cells in the lung, highlighting the utility of this approach for early stages of asthma [81]. Here, CCR2 is linked to asthma.